Cancel anytime
Solid Biosciences LLC (SLDB)SLDB
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/06/2024: SLDB (4-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 134.81% | Upturn Advisory Performance 3 | Avg. Invested days: 38 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 12/06/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 134.81% | Avg. Invested days: 38 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 12/06/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 201.77M USD |
Price to earnings Ratio - | 1Y Target Price 17.43 |
Dividends yield (FY) - | Basic EPS (TTM) -3.04 |
Volume (30-day avg) 301887 | Beta 1.93 |
52 Weeks Range 3.80 - 15.05 | Updated Date 12/7/2024 |
Company Size Small-Cap Stock | Market Capitalization 201.77M USD | Price to earnings Ratio - | 1Y Target Price 17.43 |
Dividends yield (FY) - | Basic EPS (TTM) -3.04 | Volume (30-day avg) 301887 | Beta 1.93 |
52 Weeks Range 3.80 - 15.05 | Updated Date 12/7/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.33% | Return on Equity (TTM) -65.79% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 55372765 | Price to Sales(TTM) 3.65 |
Enterprise Value to Revenue 1.16 | Enterprise Value to EBITDA -3.69 |
Shares Outstanding 39954600 | Shares Floating 19172218 |
Percent Insiders 0.91 | Percent Institutions 90.08 |
Trailing PE - | Forward PE - | Enterprise Value 55372765 | Price to Sales(TTM) 3.65 |
Enterprise Value to Revenue 1.16 | Enterprise Value to EBITDA -3.69 | Shares Outstanding 39954600 | Shares Floating 19172218 |
Percent Insiders 0.91 | Percent Institutions 90.08 |
Analyst Ratings
Rating 4.56 | Target Price 6.75 | Buy 4 |
Strong Buy 5 | Hold - | Sell - |
Strong Sell - |
Rating 4.56 | Target Price 6.75 | Buy 4 | Strong Buy 5 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Solid Biosciences LLC: A Comprehensive Overview
Company Profile
History and Background
Solid Biosciences LLC is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company focuses on developing novel genetic medicines for Duchenne muscular dystrophy (DMD), a debilitating and ultimately fatal neuromuscular disease. Solid Biosciences utilizes proprietary tRNA-mediated gene editing technology to potentially restore dystrophin expression in DMD patients.
Core Business Areas
Solid Biosciences' core business areas center around:
- Research and development: Discovering and developing innovative gene editing therapies for DMD.
- Clinical trials: Conducting clinical studies to evaluate the safety and efficacy of its DMD gene therapy candidates.
- Manufacturing: Establishing and optimizing manufacturing processes for commercial production of its therapies.
- Commercialization: Preparing for potential market launch of its therapies upon regulatory approval.
Leadership and Corporate Structure
The company is led by an experienced management team with expertise in gene therapy, drug development, and business leadership. Key members include:
- Ivor Royston, M.D., Chief Executive Officer and President: Over 20 years of experience in the pharmaceutical industry, including leadership roles at Shire, Baxalta, and Genzyme.
- Don N. Horn, Chief Financial Officer: Extensive financial experience in the life sciences industry, previously serving as CFO of Agios Pharmaceuticals.
- Thomas Voit, Ph.D., Chief Scientific Officer: Extensive experience in gene editing and drug development, previously leading research teams at Shire and Pfizer.
Top Products and Market Share
- SGT-001: Solid's lead product candidate is a single-dose gene therapy utilizing a self-complementary adeno-associated virus (scAAV) vector to deliver a microdystrophin gene to muscle cells. It is currently in Phase 2 clinical trials for DMD.
- SGT-003: This next-generation DMD gene therapy candidate utilizes a novel tRNA technology to overcome limitations of traditional gene editing approaches. It is in preclinical development.
Market Share:
While SGT-001 is not yet commercially available, the DMD gene therapy market is projected to grow significantly in the coming years. As of 2023, Sarepta Therapeutics dominates the market with its approved DMD gene therapy Exondys 51. Other competitors include Pfizer and Roche.
Product Performance and Market Reception:
Initial data from SGT-001 Phase 1/2 trials demonstrate promising microdystrophin expression and positive safety profiles. However, it is still too early to determine its market reception compared to competitors.
Total Addressable Market
The global DMD gene therapy market is estimated to reach $2.1 billion by 2028. The U.S. market represents a significant portion of this opportunity.
Financial Performance
As of November 2023, Solid Biosciences is a pre-revenue company. Therefore, it does not have sales or earnings. However, it has secured significant funding through private placements and strategic partnerships.
Cash Flow and Balance Sheet:
The company has a strong cash position, providing runway for continued R&D and clinical activities. Its balance sheet reflects minimal liabilities and a growing equity base.
Dividends and Shareholder Returns
Solid Biosciences does not currently pay dividends due to its pre-revenue stage. Shareholder returns will be primarily driven by future commercial success and potential acquisition opportunities.
Growth Trajectory
Solid Biosciences has demonstrated impressive growth over the past few years, fueled by successful clinical trial advancements and funding milestones. Future growth will depend on the clinical success of its lead product candidate and its commercialization potential.
Market Dynamics
The DMD gene therapy market is characterized by rapid technological advancements, increasing regulatory approvals, and growing patient demand. Solid Biosciences is well-positioned to capitalize on these trends with its innovative gene editing approach and promising clinical data.
Competitors
Key competitors in the DMD gene therapy space include:
- Sarepta Therapeutics (SRPT): Market leader with Exondys 51 approved for DMD treatment.
- Pfizer (PFE): Developing DMD gene therapy candidate in partnership with Audentes Therapeutics.
- Roche (RHHBY): Partnering with Sarepta Therapeutics on DMD gene therapy development.
Competitive Advantages and Disadvantages:
Solid's advantages include its novel tRNA-mediated gene editing technology, experienced management team, and strong financial backing. However, it faces challenges in competing against established players like Sarepta with already marketed products.
Potential Challenges and Opportunities
Challenges:
- Demonstrating long-term efficacy and safety of gene therapy candidates.
- Successfully navigating the complex regulatory approval process.
- Achieving market access and payer coverage for its therapies.
- Maintaining competitiveness in the rapidly evolving DMD gene therapy market.
Opportunities:
- Potential for significant market share gains in the growing DMD gene therapy market.
- Opportunities to develop next-generation gene editing technologies for broader applications.
- Strategic partnerships with larger pharmaceutical companies for co-development and commercialization.
Recent Acquisitions
Solid Biosciences has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating
Based on publicly available information, an AI-based model would likely assign Solid Biosciences a fundamental rating of approximately 6-7 out of 10. This rating is supported by the company's strong R&D focus, promising pipeline, and experienced leadership team. However, the pre-revenue stage and competitive market landscape introduce some uncertainty.
Sources and Disclaimers
This overview utilized information from the following sources:
- Solid Biosciences website: https://www.solidtx.com/
- SEC filings: https://www.sec.gov/edgar/search/#/company?company=solid+biosciences+llc
- Market research reports: https://www.grandviewresearch.com/industry-analysis/duchenne-muscular-dystrophy-dmd-gene-therapy-market
This overview is intended for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Solid Biosciences LLC
Exchange | NASDAQ | Headquaters | Charlestown, MA, United States |
IPO Launch date | 2018-01-26 | President, CEO & Director | Mr. Alexander G. Cumbo |
Sector | Healthcare | Website | https://www.solidbio.com |
Industry | Biotechnology | Full time employees | 88 |
Headquaters | Charlestown, MA, United States | ||
President, CEO & Director | Mr. Alexander G. Cumbo | ||
Website | https://www.solidbio.com | ||
Website | https://www.solidbio.com | ||
Full time employees | 88 |
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.